Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study

  • Authors:
    • Masahito Nakano
    • Takashi Niizeki
    • Hiroaki Nagamatsu
    • Masatoshi Tanaka
    • Ryoko Kuromatsu
    • Manabu Satani
    • Shusuke Okamura
    • Hideki Iwamoto
    • Shigeo Shimose
    • Tomotake Shirono
    • Yu Noda
    • Hironori Koga
    • Takuji Torimura
  • View Affiliations

  • Published online on: October 4, 2017     https://doi.org/10.3892/mco.2017.1442
  • Pages:1013-1020
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Although sorafenib and hepatic arterial infusion chemotherapy (HAIC) have been proven to improve prognosis in hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MVI), the most appropriate approach remains unclear. The present multicenter, non‑randomized, prospective cohort study aimed to compare the efficacy and safety of HAIC and sorafenib in patients with advanced HCC and MVI, without extra‑hepatic spread (EHS) and Child‑Pugh class A disease. The present study was performed between April 2008 and March 2014, and 64 HCC patients with MVI, without EHS and Child‑Pugh class A disease were registered. Of these patients, 44 were treated with HAIC and 20 with sorafenib. HAIC involved cisplatin (50 mg fine powder in 5‑10 ml lipiodol) and a continuous infusion of 5‑fluorouracil (FU) (1,500 mg/5 days), which is referred to as new 5‑FU and cisplatin therapy (NFP). The primary outcome was progression‑free survival, and the secondary outcome was overall survival (OS). Clinical factors influencing OS and the therapeutic effect were identified using univariate and multivariate analyses. There were no differences in clinical factors between the two groups. The median progression‑free survival was 5.1 and 9.5 months in the sorafenib and NFP groups, respectively (P=0.001). The complete response (CR) or partial response (PR) rates were 10 and 71% in the sorafenib and NFP groups, respectively (P<0.001). The median OS in the sorafenib and NFP groups was 13.2 and 30.4 months, respectively (P=0.013). Multivariate analysis revealed that the independent predictors of survival were Child‑Pugh score (5, P=0.022, 95% CI, 0.191‑0.892), grade of portal vein invasion (brunch, P=0.009, 95% CI, 0.220‑0.752), and therapeutic effect (CR or PR, P<0.001, 95% CI, 0.220‑0.752), and the independent predictor of therapeutic effect was therapeutic regimen (NFP, P<0.001, 95% CI, 0.006‑0.199). NFP should be the first choice for patients with advanced HCC and MVI, without EHS and Child-Pugh A disease.

Related Articles

Journal Cover

December 2017
Volume 7 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakano, M., Niizeki, T., Nagamatsu, H., Tanaka, M., Kuromatsu, R., Satani, M. ... Torimura, T. (2017). Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study. Molecular and Clinical Oncology, 7, 1013-1020. https://doi.org/10.3892/mco.2017.1442
MLA
Nakano, M., Niizeki, T., Nagamatsu, H., Tanaka, M., Kuromatsu, R., Satani, M., Okamura, S., Iwamoto, H., Shimose, S., Shirono, T., Noda, Y., Koga, H., Torimura, T."Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study". Molecular and Clinical Oncology 7.6 (2017): 1013-1020.
Chicago
Nakano, M., Niizeki, T., Nagamatsu, H., Tanaka, M., Kuromatsu, R., Satani, M., Okamura, S., Iwamoto, H., Shimose, S., Shirono, T., Noda, Y., Koga, H., Torimura, T."Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study". Molecular and Clinical Oncology 7, no. 6 (2017): 1013-1020. https://doi.org/10.3892/mco.2017.1442